Introduction
Inflammation is part of the nonspecific immune response that occurs in reaction to any type of bodily injury. Cardinal signs of inflammation are increased blood flow, elevated cellular metabolism, vasodilatation, release of soluble mediators, extravasation of fluids and cellular influx. In some disorders, the inflammatory process, which under normal conditions is self-limiting, becomes continuous and chronic, giving rise to inflammatory disease [1] . Over the last decade inflammatory immune responses have been implicated in several aspects of cardiovascular disease. Current concepts propose that the inflammation is aseptic and is not directly caused by infectious organisms. However, the precise relationship between inflammation, pathogens and cardiovascular disease remains incompletely understood. It is believed that depending on the specific disease different inflammatory pathways are of relevance. Manifestations of cardiovascular disease, such as hypertension and ischemic heart disease, are now considered to be connected to inflammation. Equally important, inflammation is now firmly recognized to participate in the process of atherosclerosis. Clinical consequences of atherosclerosis, such as myocardial infarction (MI) caused by rupture of the atherosclerotic plaque, elicit a complex inflammatory response. Depending on the context and stage of the disease, different inflammatory events are in progress.
Cytokines and cardiac outcome
Increasing evidence suggests that inflammation plays an important role in heart failure and after MI. Inflammatory cascades are propagated by proximal mediators. More than 90 cytokines and cytokine receptors have been identified [2] . The early release of cytokines shapes the nature of inflammatory responses. These responses can be beneficial, such as driving protective pathways, or detrimental, such as the induction of immunopathology.
Interleukin-6
Interleukin (IL)-6 is considered to be one of the cytokines at the top of the inflammatory cascade. It is produced by various hematopoietic and nonhematopoietic cells and exerts pro-inflammatory effects including induction of acute phase proteins in the liver. Studies on the role of IL-6 in coronary heart disease (CHD) have been relatively limited because of its short half-life and considerable intra-individual variability. However, several reports now describe IL-6 as a biomarker in CHD, highlighting a potential relevance for IL-6-mediated pathways. In a prospective study covering 2138 patients and 4267 controls, Danesh et al. [3] showed that long-term IL-6 levels are highly associated with CHD, with CHD risk gradually increasing with higher levels of circulating IL-6. One of the concerns of the authors was the influence of fluctuating IL-6 levels over time. However, in a recent study IL-6 measurements showed good reproducibility and Karakas et al. [4] propose that in clinical practice misclassification should be minimal if at least two subsequent measurements are taken. Several recent studies confirmed a risk association of IL-6 with CHD, including a possible role of IL-6 in mediating the associations of circulating inflammatory markers with risk of CHD in men [5] . In a heart failure cohort IL-6 was described as a stronger predictor of prognosis than Creactive protein [6] . Interestingly, Empana et al. [7 ] demonstrated that IL-6 is also an independent predictor of sudden death in asymptomatic European men. However, Fraser et al. [8 ] did not find strong evidence of an association between IL-6 and incident CHD in older British women after controlling for established CHD risk factors. Further studies need to address whether this could reflect a gender difference.
Pathways mediated by chronically elevated IL-6 plasma levels are associated with CHD risk but the question is whether there is already a genetic component contributing to increased IL-6 levels. Analysis of the 6 kb upstream promoter region of the IL-6 transcription start site revealed variant À6331T/C to be associated with higher IL-6 levels in an acute inflammatory state due to an Oct1 transcription-binding mechanism [9] . A prospective population-based study described an association of the IL-6 polymorphism À174 G/C with increased arterial stiffness, a precursor of cardiovascular disease [10] . The À174 G/C polymorphism has been already associated with increased IL-6 plasma levels [11] . In rheumatoid arthritis (RA) patients, who are at higher risk of developing cardiovascular disease [12] , the À174 G/C polymorphism was associated with an even higher cardiovascular disease risk, probably via increased inflammation [13] . Thus, in patient groups at higher risk of developing cardiovascular disease, genetic testing for an IL-6 polymorphism might be warranted. Of note, the À174 G/C polymorphism showed no significant association with atherosclerosis risk factors in women [14] , suggesting again a possible gender difference.
IL-6 is produced by various cell types, including cardiomyocytes, fibroblasts and inflammatory cells, after MI or after an inflammatory stimulus. So far animal studies have described a mixed picture of the effect of IL-6 and its downstream signaling. IL-6 is a member of the gp130 receptor ligand family [15] . After binding to its receptor it activates three main signaling cascades, the JAK/STAT1/ 3 signaling pathway, Ras/ERK1/2 signaling pathway and the PI3K/AKT pathway [16] (Fig. 1 , [17] [18] [19] [20] ). In animal models, high IL-6 levels are associated with adverse post-MI remodeling, and activation of gp130 was found to be cardioprotective, in contrast to the adverse outcome effects of high IL-6 levels in human studies [21] . To shed light on the role of gp130 signaling Hilfiker-Kleiner et al. [22 ] used cardiomyocyte-specific mutant mice with a mutation of the gp130 signaling including a failure to abrogate STAT3 signaling. Mutant mice displayed normal function and heart morphology after 3 months. However, after MI, sustained cardiac inflammation, increased left ventricular (LV) rupture rate, heart failure and higher mortality were observed. This was associated with a prolonged and enhanced activation of STAT3 and increased expression of IL-6. High levels of IL-6 might therefore increase adverse LV remodeling and heart failure after MI because of impaired downregulation of gp130-mediated STAT3 signaling. Therefore it seems to be of great importance to target IL-6 signaling at the right time point in disease progression. Notably, another gp130 ligand, oncostatin M (OsM), was reported to have more positive effects on inducing a prohealing environment. Recent results showed an upregulation of stromal derived factor 1 (SDF-1), a key factor in progenitor cell homing, in cardiac myocytes in vitro and in the heart in vivo after stimulation with OsM as well as upregulation of vascular endothelial growth factor (VEGF), a main factor in inducing angiogenesis [23] . 
Key points
Cytokines are important mediators of cardiovascular disease and carry the potential of being drug targets or powerful biomarkers. IL-6 is a biomarker for adverse outcome in coronary heart disease (CHD). A possible molecular explanation might be a constant activation of STAT signaling. However, pharmacologic blocking of IL-6 raises plasma levels of total cholesterol, HDL cholesterol and LDL cholesterol. Macrophage-modulating cytokines (MCP-1, fractalkine or M-CSF) are markers for adverse outcome in heart failure and might be potential drug targets. GDF-15 is a powerful biomarker in patients with CHD reflecting information from several pathological pathways.
Currently, an antibody for IL-6 receptor inhibition, tocilizumab, is used to treat patients with RA. Tocilizumab in combination with methotrexate as a treatment for RA is associated with a small but significantly increased risk of adverse events, which is comparable with that of other biologics [24] . Unexpected, however, is the reported increase of total cholesterol, HDL cholesterol and LDL cholesterol [25] . How blockade of the IL-6 pathway interferes with the regulation of lipids is not understood but obviously this is an important aspect when patients with advanced vascular disease are treated. Similarly, these findings will impact on considerations to utilize IL-6 receptor inhibition for the management of cardiovascular disease. Currently, lowering of cholesterol levels is considered a therapeutic cornerstone in the treatment of cardiovascular disease. Whether treatment-induced elevation of LDL cholesterol is associated with negative effects on cardiovascular outcomes remains to be investigated. Prospective studies will be necessary to collect relevant datasets.
Tumor necrosis factor-alpha
One of the first inflammatory pathways addressed in the setting of heart failure was tumor necrosis factor-alpha (TNF-a). Early studies identified the pro-inflammatory cytokine as a mediator of disease progression in the failing heart [26] . However, results of clinical trials using antibodies to block TNF-a gave disappointing results. In contrast to the expectations, higher rates of mortality were observed in the treated individuals as compared to the placebo control group [27] . A possible explanation might be that low physiologic levels of TNF-a might be required for proper tissue remodeling and repair. A recent report describes that TNF-a could protect cardiac mitochondria independent of its cell surface receptor [28] . Furthermore, the group of Mann showed that the cytoprotective effects of TNF-a might depend on TNF receptor-associated factor 2 in the heart [29] . According to the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology, future research should clarify the best type of anti-TNF-a therapy, the optimal dosage, and what subgroups of chronic heart failure to treat before any firm conclusions regarding efficacy in chronic heart failure can be drawn [26] . Special focus should be put on defined patient groups, for example inflammatory cardiomyopathies secondary to viral infection, to finally determine a possible use of anti-TNF-a therapy in heart disease. 2.
3.
IL-6 binds to the IL-6 receptor (1). The complex of the cytokine with the receptor then allows the recruitment and dimerization of the signaling receptor unit gp130 (2). Downstream signaling of the gp130 receptor includes activation of JAK/STAT, Akt and MEK/ERK. Activation of the JAK/STAT pathway was reported to have short-term cardioprotective effects as well as inflammation-promoting long-term effects [17] . AKT signaling in the heart includes activation of repair and regeneration pathways [18, 19] . MEK/ERK activation might lead to hypertrophy and cell survival [20] .
Monocyte chemotactic protein-1, fractalkine and macrophage colony stimulating factor Monocyte modulating cytokines have been shown to be of particular value in determining the risk of adverse events in patients with MI or heart failure. Monocyte chemotactic protein-1 (MCP-1) proved to be an independent prognostic marker in the acute and chronic phase after acute coronary syndrome (ACS) [30] . Furthermore, MCP-1 is a predictor for all cause mortality in heart failure [31] . Interestingly, MCP-1 is a chemoattractant for a pro-inflammatory subset of monocytes characterized by CD14 high CD16 low expression. In contrast, the reparative subset of monocytes, characterized by CD14 low CD16 high expression, was described to be mainly attracted by fractalkine via the receptor CX 3 CR1 [32 ] . The two subgroups of monocytes give rise to two distinct sets of macrophages, a pro-inflammatory macrophage subset expressing TNF-a, IL-1b, and myeloperoxidase, and a reparative macrophage subset expressing IL-10, transforming growth factor-b (TGF-b) and VEGF (Fig. 2a) [32 ,33] . Patients with MI show a biphasic monocyte response for the two subsets (Fig. 2b) . Pro-inflammatory monocytes peak after 3 days, whereas reparative monocytes have a peak at 5 days [34] . This biphasic monocyte pattern is in line with mouse experiments, showing a similar pattern [32 ] . Interfering with MCP-1 chemotactic signaling might be an interesting therapeutic target. An MCP-1 competitor, which was functionally inactive in CCR2 binding and calcium influx but inhibited monocyte chemotaxis or transendothelial migration, demonstrated reduced inflammatory monocyte recruitment, limited neointimal hyperplasia and attenuated myocardial ischemia-reperfusion injury in mice [35] .
Unfortunately, the effect of the MCP-1 competitor on the different subsets of monocytes was not evaluated. The two monocytic subsets might be of special interest in the setting of atherosclerosis. Atherosclerosis was reported to interfere with the infarct healing process due to an increase in pro-inflammatory monocytes [36 ] .
The recruitment of the reparative monocytic subset was described as being mainly driven by fractalkine via the receptor CX 3 CR1 [32 ] . However, fractalkine was described to be involved in the development of numerous inflammatory pathologies [37] . Attention has been mainly given to the role of fractalkine in atherosclerotic development. Animals genetically defective for fractalkine and apolipoprotein E show smaller atherosclerotic lesions. However, the role of fractalkine in respect to cardiac function and wound healing after MI needs further clarification, especially considering the data on reparative monocytes. Fractalkine was reported to be upregulated in human failing hearts and was increased in patients with chronic heart failure in accordance with disease severity. Furthermore, fractalkine itself induced the expression of markers of cardiac hypertrophy and protein phosphatases in neonatal cardiomyocytes [38] . The receptor CX 3 CR1 was described to be upregulated on monocytes from patients with heart failure [39] . Further clarification of the role of fractalkine and reparative monocytes after MI and in heart failure seems warranted.
The role of macrophage modulating cytokines in the context of MI and heart failure is currently not well understood. Cytokines mediating monocyte chemotaxis are known risk factors after MI or in heart failure. However, macrophage colony stimulating factor (M-CSF), a key survival signal for monocytes and macrophages, was even more strongly associated with all-cause mortality and the composite endpoint, implying that survival of macrophages might be a more important contributor to adverse outcome than chemotaxis in advanced heart failure [31] . Currently it is unknown whether a specific cytokine environment in heart failure might favor the pro-inflammatory macrophage or reparative macrophage subset and if M-CSF might be part of this regulatory network. Furthermore, no data is available as to whether reparative macrophages can be re-educated to pro-inflammatory macrophages in the context of heart failure.
Growth differentiation factor-15
Besides proteins modulating monocytes and macrophages, proteins expressed by macrophages also might be useful in determining the risk and outcome in patients with ACS, CHD or heart failure. Recently, growth differentiation factor 15 (GDF-15), also known as macrophage inhibitory cytokine 1, has been implicated in cardiovascular pathophysiology. GDF-15 is mainly expressed by macrophages activated by inflammatory stimuli [40] . Furthermore, cardiac myocytes under stress conditions such as stretch or inflammation have been shown to express GDF-15 [41] . The protein might control different developmental and physiological processes and tissue homeostasis and repair in adult life [42] . Although GDF-15 is not expressed or only at low abundance in the adult heart, it may be induced under certain pathologic conditions. In 2002, a link of GDF-15 with MI was proposed in healthy elderly women with no prior evidence of cardiovascular disease [43] . The study described a three times higher increased risk of future MI in women with the highest concentration of GDF-15. Future studies expanded the clinical importance of GDF-15 measurements by showing that high levels of GDF-15 predict adverse outcome in patients with HF [44 ] and that GDF-15 is a prognostic marker in patients with acute MI [45] . Additionally, GDF-15 predicted the risk of a recurrent event in patients stabilized after ACS [46] as well as the long-term outcome in patients after an episode of non-ST-segment-elevation MI [47] . Furthermore, GDF-15 was proven to be an independent marker of cardiovascular dysfunction and disease in the elderly [48] as well as in patients with heart failure and in patients with heart failure and normal ejection fraction [49] . A multiple marker approach proved that GDF-15 has incremental predictive ability over established risk factors [50] . GDF-15 might already be important in unselected patients as it proved to be an early risk stratification marker in patients with acute chest pain [51] . Although there is a lot of clinical evidence for a role of GDF-15 in heart disease, the underlying molecular mechanisms still need to be clarified. GDF-15 inhibits the secretion of TNF-a from activated macrophages. Kempf et al. [52] suggested GDF-15 as a novel defense mechanism via an AKTdependent pathway. But how GDF-15 might interact with the different macrophage subsets during MI and heart failure needs clarification. GDF-15 was recently shown to have a direct action on cardiac myocytes themselves by promoting hypertrophic growth and acting as an antiapoptotic in cultured cardiac myocytes [53] . It remains currently unknown whether the increase in GDF-15 levels seen in heart failure is a protective mechanism of the body in response to injury or if such high GDF-15 levels might be detrimental and cause disease progression.
Conclusion
Cytokines represent major mediators of inflammation and therefore are potential drug targets. IL-6 is a central player in inflammation and antibodies against IL-6 are already used in certain disease settings. Whether application of these biologics is also warranted in heart disease needs further clarification, especially because IL-6 blockade is associated with increased lipid levels in clinical trials. Macrophage modulating cytokines are more downstream in the inflammatory cascade and might therefore allow amendment of disease with greater specificity.
